Danish Elder Lymphoma Patient Hematopoietic Investigation (DELPHI)

Chemotherapy-induced Genomic Damage in Elderly Patients With Lymphoma: Prevalence, Evolution, and Clinical Consequences

Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured. However, sufficient treatment is often hampered by toxicity, especially in elderly patients. It is also well known that the main risk factor for dying of lymphoma is age. New biologically targeted therapies with fewer side effects are becoming available for lymphoma treatment, however it is currently difficult to delineate which patients benefit from chemotherapy and which should be treated with novel expensive therapies.

Recently, it has been discovered that chemotherapy can provoke growth of patient blood cells with DNA mutations. This leads to increased rates of treatment side effects and excess mortality. These defects have so far only been examined in younger patients below 70 years of age, where they are found in roughly 10% of patients. It remains unknown to what extent elderly individuals are affected, but the investigators hypothesize that the proportion and negative effects are much larger.

Therefore, the investigators propose to investigate the frequency and evolution of these DNA mutations during chemotherapy in a prospective study of patients, who are either above 60 years of age and previously treated with chemotherapy for lymphoma in a nation-wide collaboration.

By using blood samples, advanced genetic analyses and patient-reported questionnaires, the investigators will study

• The prevalence of these mutations and their consequences for patient wellbeing, treatment side effects (such as anemia, infections etc.) and mortality
• The kinetics of these mutations during and after treatment, and explore possible evolutionary patterns of the inferred damages The investigators expect to include 300 patients in the study and that the first results will be ready in a timeframe of 4 years. The investigators hope to obtain new insights in the risk factors for physiological and mental health in lymphoma patients and thereby pave the way for improvements in wellbeing and survival of this underserved population.

Study Overview

• Status: Recruiting
• Conditions: Lymphoma; Chemotherapeutic Toxicity; Chemotherapy-induced Neutropenia; Chemotherapy-Related Leukemia
• Intervention / Treatment: Diagnostic test: DNA repair gene mutation analysis

Detailed Description

DELPHI is prospective nationwide observational study investigating blood mutations in patients with lymphoma.

Inclusion criteria:

• Diagnosis of B-cell Non-Hodgkin lymphoma
• In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma
• 60 years of age or older (no age maximum)

Exclusion criteria:

• Unable to give written consent
• Non-Danish citizens

Patients will be included by their treating physcian at their local department. All analyses are centralized. Blood samples for research puporses will be taken before, midway (tipically before 3rd / 4th series depending on regimen) and 4-8 weeks after treatment. Also QOL questionaires will be sent electronically to the patients. The results of the tests performed will blinded to the patient and the treating physician.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Simon Husby, MD PhD; Phone Number: +45 3545 6060; Email: simon.husby.01@regionh.dkZZZZZZ
• Study Contact Backup: Name: Kirsten Grønbæk, Prof.

Study Locations

• Denmark
  • Copenhagen, Denmark
    • Recruiting
    • Dept. of Hematology, Rigshospitalet
    • Contact: Simon Husby, MD PhD
    • Principal Investigator: Peter Brown, MD PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Danish citizens with r/r B-cell Non-Hodgkin lymphoma 60 years of age or older.

Description

Inclusion Criteria:

• Diagnosis of r/r B-cell Non-Hodgkin lymphoma
• In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma
• 60 years of age or older (no age maximum)

Exclusion Criteria:

• Unable to give written consent
• Non-Danish citizens

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-free survival (EFS)	EFS according to Revised Lugano Criteria	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	OS	2 years

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Collaborators: Odense University Hospital; Zealand University Hospital; Aarhus University Hospital; Danish Cancer Society; Vejle Hospital; Aalborg University Hospital; Gødstrup Hospital; Sonderborg Hospital
• Investigators: Principal Investigator: Simon Husby, MD PhD, Rigshospitalet, Denmark

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): January 1, 2035

Study Registration Dates

• First Submitted: February 8, 2022
• First Submitted That Met QC Criteria: February 8, 2022
• First Posted (Actual): February 18, 2022

Study Record Updates

• Last Update Posted (Actual): December 22, 2023
• Last Update Submitted That Met QC Criteria: December 18, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Hematologic Diseases; Agranulocytosis; Leukopenia; Leukocyte Disorders; Lymphoma; Neutropenia
• Other Study ID Numbers: Delphi

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No